Chronic activation of MMP-9 can result in the release of pro-fibrotic markers leading to increasing fibroblasts released, promoting fibrogenesis and pulmonary stiffening in diabetic patients, making them more vulnerable to infections, for example COVID-19 [86,157]. Here, MMP9 is linked to COVID-19.